RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 151 filers reported holding RIGEL PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.88 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,638,602 | -21.0% | 3,369,076 | -5.7% | 0.02% | -18.5% |
| Q2 2023 | $4,606,798 | -7.5% | 3,571,161 | -5.4% | 0.03% | -12.9% |
| Q1 2023 | $4,981,061 | -23.2% | 3,773,531 | -12.7% | 0.03% | -29.5% |
| Q4 2022 | $6,483,708 | +85.6% | 4,322,472 | +46.0% | 0.04% | +57.1% |
| Q3 2022 | $3,493,000 | +3164.5% | 2,960,001 | +6569.5% | 0.03% | +2700.0% |
| Q3 2020 | $107,000 | -95.8% | 44,381 | -96.8% | 0.00% | -96.4% |
| Q2 2020 | $2,573,000 | +101.5% | 1,405,982 | +71.7% | 0.03% | +75.0% |
| Q1 2020 | $1,277,000 | -66.1% | 818,782 | -53.5% | 0.02% | -56.8% |
| Q4 2019 | $3,766,000 | +140.2% | 1,759,992 | +109.9% | 0.04% | +94.7% |
| Q3 2019 | $1,568,000 | -19.1% | 838,621 | +12.9% | 0.02% | -29.6% |
| Q2 2019 | $1,939,000 | +16.2% | 742,928 | +14.5% | 0.03% | +12.5% |
| Q1 2019 | $1,668,000 | +1959.3% | 649,028 | +2177.3% | 0.02% | +2300.0% |
| Q2 2018 | $81,000 | -91.1% | 28,500 | -92.1% | 0.00% | -94.4% |
| Q3 2017 | $913,000 | +315.0% | 359,449 | +346.0% | 0.02% | +260.0% |
| Q2 2017 | $220,000 | -83.8% | 80,600 | -85.9% | 0.01% | -80.8% |
| Q4 2016 | $1,356,000 | -42.3% | 569,822 | -11.1% | 0.03% | -38.1% |
| Q3 2016 | $2,351,000 | +59.8% | 640,722 | -2.9% | 0.04% | +40.0% |
| Q2 2016 | $1,471,000 | -0.7% | 659,522 | -7.4% | 0.03% | -3.2% |
| Q1 2016 | $1,482,000 | -34.9% | 712,538 | -5.1% | 0.03% | -31.1% |
| Q4 2015 | $2,275,000 | +20.8% | 750,738 | -1.5% | 0.04% | +15.4% |
| Q3 2015 | $1,883,000 | -11.8% | 762,491 | +14.6% | 0.04% | -4.9% |
| Q2 2015 | $2,136,000 | +67.3% | 665,491 | +86.1% | 0.04% | +86.4% |
| Q1 2015 | $1,277,000 | +17.5% | 357,607 | -25.3% | 0.02% | +15.8% |
| Q4 2014 | $1,087,000 | +12.5% | 478,989 | -3.8% | 0.02% | +18.8% |
| Q3 2014 | $966,000 | -22.5% | 497,921 | +45.0% | 0.02% | -23.8% |
| Q2 2014 | $1,247,000 | -13.3% | 343,448 | -7.3% | 0.02% | -12.5% |
| Q1 2014 | $1,438,000 | +8.2% | 370,593 | -20.5% | 0.02% | +20.0% |
| Q4 2013 | $1,329,000 | +173.5% | 466,224 | +243.6% | 0.02% | +150.0% |
| Q3 2013 | $486,000 | -40.7% | 135,700 | -44.7% | 0.01% | -42.9% |
| Q2 2013 | $820,000 | – | 245,588 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
| Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
| ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
| GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
| NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
| Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.03% |
| XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |